Viekira
- Product NDC
- 0074-0063
- 11-digit product format
- 000740063
- Labeler code
- 0074
- Product ID
- 0074-0063_75a84702-eb6d-5b0b-5091-765fa961057d
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- Dasabuvir and Ombitasvir and Paritaprevir and Ritonavir
- Dosage form
- KIT
- Labeler
- AbbVie Inc.
- Application
- NDA208624
- Marketing category
- NDA
- Marketing start
- 2016-07-22
- Marketing end
- 0000-00-00
- Active strength
- 0
- NDC exclude flag
- No
- Listing certified through
- 2020-12-31
- Current FDA listing
- Historical FDA.report record
NDC auxiliary status#
These records are reproduced from FDA’s unfinished, excluded, and compounder listings. They describe what appeared in the source files; a missing record does not establish a regulatory status. View all current auxiliary records, including entries without an NDC. · View the auxiliary file history.
| Dataset | Scope | Product NDC | Package NDC | Code | Status | Reporting period | Source date |
|---|---|---|---|---|---|---|---|
| excluded product | product | 0074-0063 | D | Discontinued by firm | 2026-08-10 | ||
| excluded package | package | 0074-0063 | 0074-0063-01 | D | Discontinued by firm | 2026-08-10 | |
| excluded package | package | 0074-0063 | 0074-0063-28 | D | Discontinued by firm | 2026-08-10 |
Observed NDC auxiliary status history#
This history shows the information present in each captured FDA auxiliary file. It is not a continuous regulatory timeline, and a missing record does not establish a status.
| Captured / source date | Dataset | Scope | Package NDC | Snapshot | Source SHA-256 |
|---|---|---|---|---|---|
| 2025-12-14 17:58 UTC · source 2025-12-05 | excluded product | product | d630ba8d3edf… | 732f749b63fb… | |
| 2025-12-14 17:58 UTC · source 2025-12-05 | excluded package | package | 0074-0063-28 | d630ba8d3edf… | 732f749b63fb… |
| 2025-12-14 17:58 UTC · source 2025-12-05 | excluded package | package | 0074-0063-01 | d630ba8d3edf… | 732f749b63fb… |
| 2025-08-27 00:01 UTC · source 2025-08-26 | excluded product | product | f5e01cc5f278… | a2eaf40c39c3… | |
| 2025-08-27 00:01 UTC · source 2025-08-26 | excluded package | package | 0074-0063-28 | f5e01cc5f278… | a2eaf40c39c3… |
| 2025-08-27 00:01 UTC · source 2025-08-26 | excluded package | package | 0074-0063-01 | f5e01cc5f278… | a2eaf40c39c3… |
| 2025-04-01 02:39 UTC · source 2025-03-31 | excluded product | product | 2ef7874e63bc… | 57b86245f4fa… | |
| 2025-04-01 02:39 UTC · source 2025-03-31 | excluded package | package | 0074-0063-28 | 2ef7874e63bc… | 57b86245f4fa… |
| 2025-04-01 02:39 UTC · source 2025-03-31 | excluded package | package | 0074-0063-01 | 2ef7874e63bc… | 57b86245f4fa… |
| 2025-03-28 20:22 UTC · source 2025-03-28 | excluded product | product | a1b67e2a42f9… | c4cf2c586c0d… | |
| 2025-03-28 20:22 UTC · source 2025-03-28 | excluded package | package | 0074-0063-28 | a1b67e2a42f9… | c4cf2c586c0d… |
| 2025-03-28 20:22 UTC · source 2025-03-28 | excluded package | package | 0074-0063-01 | a1b67e2a42f9… | c4cf2c586c0d… |
| 2025-03-22 03:12 UTC · source 2025-03-21 | excluded product | product | cfe11265f3b6… | 090c488252e2… | |
| 2025-03-22 03:12 UTC · source 2025-03-21 | excluded package | package | 0074-0063-28 | cfe11265f3b6… | 090c488252e2… |
| 2025-03-22 03:12 UTC · source 2025-03-21 | excluded package | package | 0074-0063-01 | cfe11265f3b6… | 090c488252e2… |
| 2025-03-10 12:48 UTC · source 2025-03-10 | excluded product | product | cdf11ea48f46… | ba0047e9e063… | |
| 2025-03-10 12:48 UTC · source 2025-03-10 | excluded package | package | 0074-0063-28 | cdf11ea48f46… | ba0047e9e063… |
| 2025-03-10 12:48 UTC · source 2025-03-10 | excluded package | package | 0074-0063-01 | cdf11ea48f46… | ba0047e9e063… |
| 2025-02-02 03:52 UTC · source 2025-01-31 | excluded product | product | 302b2466d912… | e7b80fea0513… | |
| 2025-02-02 03:52 UTC · source 2025-01-31 | excluded package | package | 0074-0063-28 | 302b2466d912… | e7b80fea0513… |
| 2025-02-02 03:52 UTC · source 2025-01-31 | excluded package | package | 0074-0063-01 | 302b2466d912… | e7b80fea0513… |
| 2025-01-20 13:05 UTC · source 2025-01-20 | excluded product | product | ed331223b511… | 672a5bd82f5f… | |
| 2025-01-20 13:05 UTC · source 2025-01-20 | excluded package | package | 0074-0063-28 | ed331223b511… | 672a5bd82f5f… |
| 2025-01-20 13:05 UTC · source 2025-01-20 | excluded package | package | 0074-0063-01 | ed331223b511… | 672a5bd82f5f… |
| 2025-01-11 03:41 UTC · source 2025-01-10 | excluded product | product | 0efc9e666f02… | f202fb6c5f17… | |
| 2025-01-11 03:41 UTC · source 2025-01-10 | excluded package | package | 0074-0063-28 | 0efc9e666f02… | f202fb6c5f17… |
| 2025-01-11 03:41 UTC · source 2025-01-10 | excluded package | package | 0074-0063-01 | 0efc9e666f02… | f202fb6c5f17… |
| 2024-11-09 02:27 UTC · source 2024-11-08 | excluded product | product | ad56d346431e… | cc804d4bbf1e… | |
| 2024-11-09 02:27 UTC · source 2024-11-08 | excluded package | package | 0074-0063-28 | ad56d346431e… | cc804d4bbf1e… |
| 2024-11-09 02:27 UTC · source 2024-11-08 | excluded package | package | 0074-0063-01 | ad56d346431e… | cc804d4bbf1e… |
| 2024-10-04 04:10 UTC · source 2024-10-03 | excluded product | product | 367a005e9d99… | 383a685ebd0f… | |
| 2024-10-04 04:10 UTC · source 2024-10-03 | excluded package | package | 0074-0063-28 | 367a005e9d99… | 383a685ebd0f… |
| 2024-10-04 04:10 UTC · source 2024-10-03 | excluded package | package | 0074-0063-01 | 367a005e9d99… | 383a685ebd0f… |
| 2024-07-10 04:00 UTC · source 2024-07-09 | excluded product | product | 557ba5c1ecfa… | 9c80585c8c6e… | |
| 2024-07-10 04:00 UTC · source 2024-07-09 | excluded package | package | 0074-0063-28 | 557ba5c1ecfa… | 9c80585c8c6e… |
| 2024-07-10 04:00 UTC · source 2024-07-09 | excluded package | package | 0074-0063-01 | 557ba5c1ecfa… | 9c80585c8c6e… |
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| N208624-001 | VIEKIRA XR | DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR | EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET, EXTENDED RELEASE / ORAL | RLD | 2016-07-22 |
Orange Book patents#
| Application-product | Patent | Expiration | Use code | Coverage / status | Submission date |
|---|---|---|---|---|---|
| N208624-001 | 8501238 | 2028-09-17 | U-1636 | Drug substance, Drug product | 2016-08-17 |
| N208624-001 | 9139536 | 2028-11-09 | U-1753 | 2016-08-17 | |
| N208624-001 | 8188104 | 2029-05-17 | U-1636 | Drug substance, Drug product | 2016-08-17 |
| N208624-001 | 8642538 | 2029-09-10 | U-1638 | Drug substance, Drug product | 2016-08-17 |
| N208624-001 | 9006387 | 2030-06-10 | U-1687 | 2016-08-17 | |
| N208624-001 | 8420596 | 2031-04-10 | Drug substance, Drug product | 2016-08-17 | |
| N208624-001 | 9044480 | 2031-04-10 | U-1638 | 2016-08-17 | |
| N208624-001 | 8686026 | 2031-06-09 | Drug product | 2016-08-17 | |
| N208624-001 | 8691938 | 2032-04-13 | Drug substance, Drug product | 2016-08-17 | |
| N208624-001 | 10201541 | 2032-05-17 | Drug product | 2019-03-14 | |
| N208624-001 | 10201584 | 2032-05-17 | U-1889 | 2019-03-14 | |
| N208624-001 | 8466159 | 2032-09-04 | U-1637 | 2016-08-17 | |
| N208624-001 | 8492386 | 2032-09-04 | U-1840 | 2016-08-17 | |
| N208624-001 | 8680106 | 2032-09-04 | U-1637 | 2016-08-17 | |
| N208624-001 | 8685984 | 2032-09-04 | U-1840 | 2016-08-17 | |
| N208624-001 | 10105365 | 2035-01-02 | U-1889 | Drug product | 2018-11-20 |
| N208624-001 | 9333204 | 2035-01-02 | U-1889 | Drug product | 2016-08-17 |
| N208624-001 | 9744170 | 2035-01-02 | U-1889 | Drug product | 2017-09-27 |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-02-19 14:30 UTC | 2026-02 | N208624-001 | VIEKIRA XR | EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET, EXTENDED RELEASE / ORAL | RLD | 2016-07-22 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N208624-001 | VIEKIRA XR | EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET, EXTENDED RELEASE / ORAL | RLD | 2016-07-22 | 31067a03dcf5… | |
| 2025-08-23 18:47 UTC | 2025-08 | N208624-001 | VIEKIRA XR | EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET, EXTENDED RELEASE / ORAL | RLD | 2016-07-22 | 6a471c1ec25d… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N208624-001 | VIEKIRA XR | EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET, EXTENDED RELEASE / ORAL | RLD | 2016-07-22 | fd3edfee7708… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N208624-001 | VIEKIRA XR | EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET, EXTENDED RELEASE / ORAL | RLD | 2016-07-22 | b8a1b40f171c… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N208624-001 | VIEKIRA XR | EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET, EXTENDED RELEASE / ORAL | RLD | 2016-07-22 | 03ed91905a0d… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N208624-001 | VIEKIRA XR | EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET, EXTENDED RELEASE / ORAL | RLD | 2016-07-22 | 2680178bc6a6… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N208624-001 | VIEKIRA XR | EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET, EXTENDED RELEASE / ORAL | RLD | 2016-07-22 | 5bbf6a4d5a75… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N208624-001 | VIEKIRA XR | EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET, EXTENDED RELEASE / ORAL | RLD | 2016-07-22 | d8e5a09893c0… | |
| 2024-10-29 15:01 UTC | 2024-10 | N208624-001 | VIEKIRA XR | EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET, EXTENDED RELEASE / ORAL | RLD | 2016-07-22 | d06236e962d9… | |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N208624-001 | VIEKIRA XR | EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET, EXTENDED RELEASE / ORAL | RLD | 2016-07-22 | 79d66fd596c7… | |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | N208624-001 | VIEKIRA XR | EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET, EXTENDED RELEASE / ORAL | RLD | 2016-07-22 | 301d65b070ca… | |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | N208624-001 | VIEKIRA XR | EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET, EXTENDED RELEASE / ORAL | RLD | 2016-07-22 | 1e350fbaab3a… | |
| 2024-05-31 18:47 UTC | 2024-05 | N208624-001 | VIEKIRA XR | EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET, EXTENDED RELEASE / ORAL | RLD | 2016-07-22 | 8072bd15b7f6… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N208624-001 | VIEKIRA XR | EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET, EXTENDED RELEASE / ORAL | RLD | 2016-07-22 | 5c6f7cd8ea54… | |
| 2022-04-08 23:34 UTC | 2022-04 | N208624-001 | VIEKIRA XR | EQ 200MG BASE;8.33MG;50MG;33.33MG | TABLET, EXTENDED RELEASE / ORAL | RLD | 2016-07-22 | 5d02ea3f76ae… | |
| 2022-04-04 05:41 UTC | 2022-04 | N208624-001 | VIEKIRA XR | EQ 200MG BASE;8.33MG;50MG;33.33MG | TABLET, EXTENDED RELEASE / ORAL | RLD | 2016-07-22 | 4b0b4de00fa7… | |
| 2019-12-13 00:20 UTC | 2019-12 | N208624-001 | VIEKIRA XR | EQ 200MG BASE;8.33MG;50MG;33.33MG | TABLET, EXTENDED RELEASE / ORAL | RLD | 2016-07-22 | 74a2ff9319b5… | |
| 2022-03-09 01:35 UTC | 2022-03 | N208624-001 | VIEKIRA XR | EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET, EXTENDED RELEASE / ORAL | RLD | 2016-07-22 | bb7c543d1eb4… | |
| 2021-12-28 21:50 UTC | 2021-12 | N208624-001 | VIEKIRA XR | EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** | TABLET, EXTENDED RELEASE / ORAL | RLD | 2016-07-22 | 782e0a99824c… | |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | N208624-001 | VIEKIRA XR | EQ 200MG BASE;8.33MG;50MG;33.33MG | TABLET, EXTENDED RELEASE / ORAL | RLD | 2016-07-22 | 87673890dc5c… | |
| 2021-03-12 10:30 UTC | 2021-03 | N208624-001 | VIEKIRA XR | EQ 200MG BASE;8.33MG;50MG;33.33MG | TABLET, EXTENDED RELEASE / ORAL | RLD | 2016-07-22 | 5aa47cf7b7d7… | |
| 2020-12-22 03:56 UTC | 2020-12 | N208624-001 | VIEKIRA XR | EQ 200MG BASE;8.33MG;50MG;33.33MG | TABLET, EXTENDED RELEASE / ORAL | RLD | 2016-07-22 | 8869cabd3fbd… | |
| 2020-11-12 02:37 UTC | 2020-11 | N208624-001 | VIEKIRA XR | EQ 200MG BASE;8.33MG;50MG;33.33MG | TABLET, EXTENDED RELEASE / ORAL | RLD | 2016-07-22 | c0c555d07b60… | |
| 2019-12-14 00:12 UTC | 2019-12 | N208624-001 | VIEKIRA XR | EQ 200MG BASE;8.33MG;50MG;33.33MG | TABLET, EXTENDED RELEASE / ORAL | RLD | 2016-07-22 | 3f01610625f2… | |
| 2019-09-15 20:21 UTC | 2019-09 | N208624-001 | VIEKIRA XR | EQ 200MG BASE;8.33MG;50MG;33.33MG | TABLET, EXTENDED RELEASE / ORAL | RLD | 2016-07-22 | b00525d2431f… | |
| 2019-07-19 19:46 UTC | 2019-07 | N208624-001 | VIEKIRA XR | EQ 200MG BASE;8.33MG;50MG;33.33MG | TABLET, EXTENDED RELEASE / ORAL | RLD | 2016-07-22 | ea99ee380514… | |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | N208624-001 | VIEKIRA XR | EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET, EXTENDED RELEASE / ORAL | RLD | 2016-07-22 | 6a51e52b5d6a… | |
| 2024-02-18 07:12 UTC | 2024-02 | N208624-001 | VIEKIRA XR | EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET, EXTENDED RELEASE / ORAL | RLD | 2016-07-22 | 1c564ffb4f44… | |
| 2023-12-20 04:57 UTC | 2023-12 | N208624-001 | VIEKIRA XR | EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET, EXTENDED RELEASE / ORAL | RLD | 2016-07-22 | ea1830bbd6c7… | |
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | N208624-001 | VIEKIRA XR | EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET, EXTENDED RELEASE / ORAL | RLD | 2016-07-22 | a72a2bbeb626… | |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | N208624-001 | VIEKIRA XR | EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET, EXTENDED RELEASE / ORAL | RLD | 2016-07-22 | 9b2671bbb829… | |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | N208624-001 | VIEKIRA XR | EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET, EXTENDED RELEASE / ORAL | RLD | 2016-07-22 | a67488948f0b… | |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | N208624-001 | VIEKIRA XR | EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET, EXTENDED RELEASE / ORAL | RLD | 2016-07-22 | 3f0d92c62455… | |
| 2023-05-13 08:27 UTC | 2023-05 | N208624-001 | VIEKIRA XR | EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET, EXTENDED RELEASE / ORAL | RLD | 2016-07-22 | 053a50430f4f… | |
| 2023-01-26 05:58 UTC | 2023-01 | N208624-001 | VIEKIRA XR | EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET, EXTENDED RELEASE / ORAL | RLD | 2016-07-22 | 3bdfa0b2c4d7… | |
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | N208624-001 | VIEKIRA XR | EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET, EXTENDED RELEASE / ORAL | RLD | 2016-07-22 | 3a93d1ddd44b… | |
| 2022-10-28 04:53 UTC | 2022-10 | N208624-001 | VIEKIRA XR | EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET, EXTENDED RELEASE / ORAL | RLD | 2016-07-22 | f41ea6bd6efb… | |
| 2022-09-29 23:25 UTC | 2022-09 | N208624-001 | VIEKIRA XR | EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET, EXTENDED RELEASE / ORAL | RLD | 2016-07-22 | e64feba35796… | |
| 2022-07-09 03:26 UTC · 3 captures of this ZIP | 2022-07 | N208624-001 | VIEKIRA XR | EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET, EXTENDED RELEASE / ORAL | RLD | 2016-07-22 | cb3db0bc1861… |
Observed Orange Book patent history#
| Captured | Edition | Application-product | Patent | Expiration | Use code | Coverage / status | Submission date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|
| 2026-02-19 14:30 UTC | 2026-02 | N208624-001 | 8501238 | 2028-09-17 | U-1636 | Drug substance, Drug product | 2016-08-17 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N208624-001 | 9139536 | 2028-11-09 | U-1753 | 2016-08-17 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N208624-001 | 8188104 | 2029-05-17 | U-1636 | Drug substance, Drug product | 2016-08-17 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N208624-001 | 8642538 | 2029-09-10 | U-1638 | Drug substance, Drug product | 2016-08-17 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N208624-001 | 9006387 | 2030-06-10 | U-1687 | 2016-08-17 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N208624-001 | 8420596 | 2031-04-10 | Drug substance, Drug product | 2016-08-17 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N208624-001 | 9044480 | 2031-04-10 | U-1638 | 2016-08-17 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N208624-001 | 8686026 | 2031-06-09 | Drug product | 2016-08-17 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N208624-001 | 8691938 | 2032-04-13 | Drug substance, Drug product | 2016-08-17 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N208624-001 | 10201541 | 2032-05-17 | Drug product | 2019-03-14 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N208624-001 | 10201584 | 2032-05-17 | U-1889 | 2019-03-14 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N208624-001 | 8466159 | 2032-09-04 | U-1637 | 2016-08-17 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N208624-001 | 8492386 | 2032-09-04 | U-1840 | 2016-08-17 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N208624-001 | 8680106 | 2032-09-04 | U-1637 | 2016-08-17 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N208624-001 | 8685984 | 2032-09-04 | U-1840 | 2016-08-17 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N208624-001 | 10105365 | 2035-01-02 | U-1889 | Drug product | 2018-11-20 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N208624-001 | 9333204 | 2035-01-02 | U-1889 | Drug product | 2016-08-17 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N208624-001 | 9744170 | 2035-01-02 | U-1889 | Drug product | 2017-09-27 | 011fe1cb6892… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N208624-001 | 8501238 | 2028-09-17 | U-1636 | Drug substance, Drug product | 2016-08-17 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N208624-001 | 9139536 | 2028-11-09 | U-1753 | 2016-08-17 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N208624-001 | 8188104 | 2029-05-17 | U-1636 | Drug substance, Drug product | 2016-08-17 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N208624-001 | 8642538 | 2029-09-10 | U-1638 | Drug substance, Drug product | 2016-08-17 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N208624-001 | 9006387 | 2030-06-10 | U-1687 | 2016-08-17 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N208624-001 | 8420596 | 2031-04-10 | Drug substance, Drug product | 2016-08-17 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N208624-001 | 9044480 | 2031-04-10 | U-1638 | 2016-08-17 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N208624-001 | 8686026 | 2031-06-09 | Drug product | 2016-08-17 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N208624-001 | 8691938 | 2032-04-13 | Drug substance, Drug product | 2016-08-17 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N208624-001 | 10201541 | 2032-05-17 | Drug product | 2019-03-14 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N208624-001 | 10201584 | 2032-05-17 | U-1889 | 2019-03-14 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N208624-001 | 8466159 | 2032-09-04 | U-1637 | 2016-08-17 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N208624-001 | 8492386 | 2032-09-04 | U-1840 | 2016-08-17 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N208624-001 | 8680106 | 2032-09-04 | U-1637 | 2016-08-17 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N208624-001 | 8685984 | 2032-09-04 | U-1840 | 2016-08-17 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N208624-001 | 10105365 | 2035-01-02 | U-1889 | Drug product | 2018-11-20 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N208624-001 | 9333204 | 2035-01-02 | U-1889 | Drug product | 2016-08-17 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N208624-001 | 9744170 | 2035-01-02 | U-1889 | Drug product | 2017-09-27 | 31067a03dcf5… |
| 2025-08-23 18:47 UTC | 2025-08 | N208624-001 | 8501238 | 2028-09-17 | U-1636 | Drug substance, Drug product | 2016-08-17 | 6a471c1ec25d… |
| 2025-08-23 18:47 UTC | 2025-08 | N208624-001 | 9139536 | 2028-11-09 | U-1753 | 2016-08-17 | 6a471c1ec25d… | |
| 2025-08-23 18:47 UTC | 2025-08 | N208624-001 | 8188104 | 2029-05-17 | U-1636 | Drug substance, Drug product | 2016-08-17 | 6a471c1ec25d… |
| 2025-08-23 18:47 UTC | 2025-08 | N208624-001 | 8642538 | 2029-09-10 | U-1638 | Drug substance, Drug product | 2016-08-17 | 6a471c1ec25d… |
Observed Orange Book exclusivity history#
| Captured | Edition | Application-product | Exclusivity code | Expiration | Source SHA-256 |
|---|---|---|---|---|---|
| 2019-12-13 00:20 UTC | 2019-12 | N208624-001 | NCE | 2019-12-19 | 74a2ff9319b5… |
| 2019-12-14 00:12 UTC | 2019-12 | N208624-001 | NCE | 2019-12-19 | 3f01610625f2… |
| 2019-09-15 20:21 UTC | 2019-09 | N208624-001 | NCE | 2019-12-19 | b00525d2431f… |
| 2019-07-19 19:46 UTC | 2019-07 | N208624-001 | NCE | 2019-12-19 | ea99ee380514… |